Physician profile
Maria E Gallo
NPI 1396181103
$416.15
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.09 · 2021: $49.08 · 2022: $133 · 2023: $112 · 2024: $33.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.85 | 2022-2024 | |
| Sanofi Pasteur INC. | $62.62 | 2019-2021 | |
| Pfizer INC. | $40.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.47 | 2022 | |
| Glaxosmithkline, LLC. | $32.80 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $30.38 | 2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $23.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.14 | 2023 | Trulance, Xifaxan |
| Amgen INC. | $14.94 | 2023 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $14.54 | 2022 | |
| Strongbridge US INC. | $14.03 | 2019 | |
| Heartflow, INC. | $13.58 | 2022 | |
| Merck Sharp & Dohme LLC | $11.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.